A patient journey map for people living with autoimmune pulmonary alveolar proteinosis

被引:0
|
作者
Ataya, Ali [1 ]
Plomaritis, Niki [2 ]
Rhee, Michele [3 ]
Sathyanarayanan, Swaminathan Perinkulam [1 ]
Robinson, Brian [3 ]
机构
[1] Univ Florida, Div Pulm Crit Care & Sleep Med, 1549 Gale Lemerand Dr, Gainesville, FL 32610 USA
[2] PAP Fdn, 3333 Burnet Ave, Cincinnati, OH 45229 USA
[3] Savara Inc, 1717 Langhorne Newtown Rd, Langhorne, PA 19047 USA
关键词
Autoimmune pulmonary alveolar proteinosis; Pulmonary alveolar proteinosis; Patient journey map; Patient experience map; GM-CSF; Whole lung lavage; Interstitial lung disease; REPORTING QUALITATIVE RESEARCH; DIAGNOSIS;
D O I
10.1016/j.rmed.2025.107990
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Patients with autoimmune pulmonary alveolar proteinosis (PAP) face a complicated journey (physically, emotionally, and financially) to receive the correct diagnosis and treatment. We developed a patient journey map (PJM) to describe the experiences and needs of patients with autoimmune PAP in the USA. Methods: This PJM was developed in four stages: (1) analysis of existing literature; (2) patient advisory board meetings (n = 7); (3) an online survey (n = 19); and (4) a validation workshop (n = 6). Results: Four phases of the patient journey were identified: (1) symptoms and experience before diagnosis; (2) diagnosis; (3) treatment; and (4) ongoing monitoring. Patients reported heterogeneous and indirect diagnostic pathways, often waiting months or years for the correct diagnosis. The majority reported at least one misdiagnosis, most commonly pneumonia. Treatment pathways varied substantially, and current treatments and offlabel therapies were frequently described as burdensome, emotionally taxing, and/or financially worrisome. Patients described their journey as an "emotional rollercoaster," especially during pre-diagnosis and treatment. Patients reported common barriers to care, particularly insurance problems and access to expert care. Patients specifically cited the need for improved education on autoimmune PAP within the medical community and increased help with insurance challenges related to current treatments. Conclusions: This PJM provides insights on patients' journeys with autoimmune PAP. Patients reported inconsistent, burdensome, and circuitous journeys. This PJM provides the medical community with valuable information on patients' needs and increases awareness of this rare disease. Over time, these factors may improve diagnosis, treatment, and the holistic experience of patients with autoimmune PAP.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] A novel rodent model for autoimmune pulmonary alveolar proteinosis
    Ferretti, Andrew
    Fortwendel, Jarrod
    Gebb, Sarah
    Barrington, Robert
    JOURNAL OF IMMUNOLOGY, 2015, 194
  • [32] Rituximab rescue therapy for autoimmune pulmonary alveolar proteinosis
    Bird, Daniel
    Evans, Jack
    Pahoff, Carl
    RESPIRATORY MEDICINE CASE REPORTS, 2022, 37
  • [33] Autoimmune pulmonary alveolar proteinosis prior to myelodysplastic syndrome
    Foo, Chuan Tai
    Chhor, Louis
    Thien, Francis
    RESPIROLOGY CASE REPORTS, 2020, 8 (05):
  • [34] Autoimmune Pulmonary Alveolar Proteinosis Complicated by Myelodysplastic Syndrome
    Shimaya, Minako
    Inagaki, Yuji
    Arai, Toru
    Kawakami, Mayu
    Takeuchi, Naoko
    Sumikawa, Hiromitsu
    Shimizu, Shigeki
    Takimoto, Takayuki
    Inoue, Yoshikazu
    INTERNAL MEDICINE, 2024, 63 (10) : 1451 - 1457
  • [35] Lentivirus Gene Therapy for Autoimmune Pulmonary Alveolar Proteinosis
    Palau, Helena
    Meng, Cuixiang
    Bhargava, Anushka
    Pilou, Aikaterini
    Atsumi, Naoko
    Byrne, Adam
    Pringle, Ian
    Ashworth, Rachel
    Chan, Mario
    Gill, Deborah
    Hyde, Stephen
    Morgan, Cliff
    Alton, Eric
    Griesenbach, Uta
    MOLECULAR THERAPY, 2019, 27 (04) : 43 - 44
  • [36] Revitalizing Alveolar Immunity: MSC role in Autoimmune Pulmonary Alveolar Proteinosis
    Song, Xinyu
    Jin, Jing
    Zhang, Mengni
    Zhu, Yiping
    Li, Shiyue
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [37] Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis
    Sakaue, Saori
    Yamaguchi, Etsuro
    Inoue, Yoshikazu
    Takahashi, Meiko
    Hirata, Jun
    Suzuki, Ken
    Ito, Satoru
    Arai, Toru
    Hirose, Masaki
    Tanino, Yoshinori
    Nikaido, Takefumi
    Ichiwata, Toshio
    Ohkouchi, Shinya
    Hirano, Taizou
    Takada, Toshinori
    Miyawaki, Satoru
    Dofuku, Shogo
    Maeda, Yuichi
    Nii, Takuro
    Kishikawa, Toshihiro
    Ogawa, Kotaro
    Masuda, Tatsuo
    Yamamoto, Kenichi
    Sonehara, Kyuto
    Tazawa, Ryushi
    Morimoto, Konosuke
    Takaki, Masahiro
    Konno, Satoshi
    Suzuki, Masaru
    Tomii, Keisuke
    Nakagawa, Atsushi
    Handa, Tomohiro
    Tanizawa, Kiminobu
    Ishii, Haruyuki
    Ishida, Manabu
    Kato, Toshiyuki
    Takeda, Naoya
    Yokomura, Koshi
    Matsui, Takashi
    Watanabe, Masaki
    Inoue, Hiromasa
    Imaizumi, Kazuyoshi
    Goto, Yasuhiro
    Kida, Hiroshi
    Fujisawa, Tomoyuki
    Suda, Takafumi
    Yamada, Takashi
    Satake, Yasuomi
    Ibata, Hidenori
    Hizawa, Nobuyuki
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [38] A Novel Rodent Model For Autoimmune Pulmonary Alveolar ProteINOSis
    Ferretti, A. P.
    Barrington, R. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [39] Autoimmune pulmonary alveolar proteinosis and sarcoidosis in the same patient: Case report and systematic review
    Shrestha, Deepa
    Muthu, Valliappan
    Sehgal, Inderpaul
    Bal, Amanjit
    Agarwal, Ritesh
    Dhooria, Sahajal
    LUNG INDIA, 2022, 39 (05) : 466 - 469
  • [40] Autoimmune pulmonary alveolar proteinosis with primary lung cancer in a patient of very advanced years
    Iwakami, Shin-ichiro
    Fujii, Mitsuhiro
    Tsutsumi, Takeo
    Sekimoto, Yasuhito
    Jo, Hitomi
    Hara, Munechika
    Iwakami, Naoko
    Takahashi, Kazuhisa
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2015, 15 (05) : 666 - 667